David R.W. Jayne Form 3 Aurinia Pharmaceuticals / David R.W. Jayne ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Jayne David R.W.

(Last)

(First)

(Middle)

#1203-4464 MARKHAM STREET

(Street)

VICTORIA

V8Z7X8

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/01/2021

3. Issuer Name and Ticker or Trading Symbol
Aurinia Pharmaceuticals Inc. [ AUPH ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	30,000	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy)	⁽¹⁾	02/16/2027	Common Stock	10,000	3.62⁽²⁾	D
Stock Option (right to buy)	⁽¹⁾	02/16/2027	Common Stock	20,000	6.95⁽²⁾	D
Stock Option (right to buy)	⁽¹⁾	02/05/2028	Common Stock	30,000	5.14⁽²⁾	D
Stock Option (right to buy)	⁽¹⁾	01/20/2029	Common Stock	30,000	6.06⁽²⁾	D
Stock Option (right to buy)	⁽¹⁾	07/03/2029	Common Stock	15,000	6.42⁽²⁾	D
Stock Option (right to buy)	⁽³⁾	06/02/2030	Common Stock	30,000	15.75	D

Explanation of Responses:

1. The shares subject to the option are fully vested and immediately exercisable. They vested in twelve equal monthly installments from the grant date.

2. Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date.

3. The shares subject to the option vest in twelve equal monthly installments from the grant date.

Remarks:

	/s/ Stephen Robertson, Attorney-in-Fact for David R.W. Jayne, M.D.	01/04/2021
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

David R.W. Jayne Form 3Aurinia Pharmaceuticals / David R.W. Jayne ownership change